Company logo

MCRB - Seres Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United States
Type: Equity

MCRB price evolution
MCRB
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $81.11 $119.61 $136.15
Short term investments
Net receivables $18.6 $7.42 $8.67
Inventory $53 $41.97 $29.65
Total current assets $72.93 $149.26 $165.18 $175.41
Long term investments $1.4 $1.4
Property, plant & equipment $95.48 $121.08 $124.78 $132.25
Goodwill & intangible assets
Total noncurrent assets $172.47 $176.08 $183.19
Total investments $1.4 $1.4
Total assets $178.74 $321.73 $341.26 $358.6
Current liabilities
Accounts payable $8.25 $4.81 $5.22 $3.64
Deferred revenue $103.29 $103.47 $103.09
Short long term debt $9.2 $8.83 $6.68
Total current liabilities $64.83 $108.28 $98.48 $98.66
Long term debt $203.43 $205.35 $207.26
Total noncurrent liabilities $300.52 $302.52 $304.8
Total debt $212.63 $214.18 $213.94
Total liabilities $154.82 $408.81 $401 $403.46
Shareholders' equity
Retained earnings -$962.46 -$1051.24 -$1018.37 -$978.24
Other shareholder equity
Total shareholder equity -$87.07 -$59.74 -$44.86
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $136.15 $171.22 $188 $116.05
Short term investments $18.31 $110.7 $137.57
Net receivables $8.67 $9.39
Inventory $29.65
Total current assets $175.41 $194.76 $303.63 $268.78
Long term investments $1.4 $1.4 $1.9 $51.23
Property, plant & equipment $132.25 $133.97 $36.15 $22.94
Goodwill & intangible assets
Total noncurrent assets $183.19 $154.02 $51.23 $74.16
Total investments $1.4 $19.71 $112.6 $188.79
Total assets $358.6 $348.78 $354.86 $342.94
Current liabilities
Accounts payable $3.64 $17.44 $13.73 $4.02
Deferred revenue $103.09 $96.69 $103.82 $108.17
Short long term debt $6.68 $4.06 $6.61 $5.57
Total current liabilities $98.66 $85.6 $82.26 $46.41
Long term debt $207.26 $50.59 $42.6 $35.2
Total noncurrent liabilities $304.8 $252.41 $141.09 $121.78
Total debt $213.94 $162.59 $49.21 $40.77
Total liabilities $403.46 $338 $223.35 $168.19
Shareholders' equity
Retained earnings -$978.24 -$864.51 -$614.35 -$548.78
Other shareholder equity -$0.01 -$0.06 -$0.05
Total shareholder equity -$44.86 $10.78 $131.51 $174.75
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $0.06
Cost of revenue
Gross Profit $0.06
Operating activities
Research & development $17.88 $21.7 $26.85
Selling, general & administrative $16.06 $15.47 $17.23
Total operating expenses $31.34 $39.59 $39.59
Operating income -$31.34 -$39.59 -$39.53
Income from continuing operations
EBIT -$29.42 -$35.47 -$37.22
Income tax expense
Interest expense $3.45 $4.66 $4.03
Net income
Net income -$32.87 -$40.13 -$41.25
Income (for common shares) -$32.87 -$40.13 -$41.25
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $126.33 $7.13 $144.93 $33.22
Cost of revenue
Gross Profit $126.33 $7.13 $144.93 $33.22
Operating activities
Research & development $145.86 $172.92 $141.89 $90.57
Selling, general & administrative $87.74 $79.69 $69.26 $30.77
Total operating expenses $234.31 $253.62 $209.42 $121.34
Operating income -$107.98 -$246.49 -$64.49 -$88.13
Income from continuing operations
EBIT -$100.55 -$244.14 -$62.67 -$86.2
Income tax expense
Interest expense $13.18 $6.02 $2.91 $2.92
Net income
Net income -$113.72 -$250.16 -$65.58 -$89.13
Income (for common shares) -$113.72 -$250.16 -$65.58 -$89.13
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$32.87 -$40.13 -$41.25
Operating activities
Depreciation $3.81 $3.95 $4.05
Business acquisitions & disposals
Stock-based compensation $5.53 $6.49 $5.09
Total cash flows from operations -$39.81 -$35.24 -$47.5
Investing activities
Capital expenditures -$0.1 -$0.06 -$0.88
Investments $1.4
Total cash flows from investing $142.38 $1.3 -$0.06 -$0.88
Financing activities
Dividends paid
Sale and purchase of stock $18.76 $6.43
Net borrowings
Total cash flows from financing -$92.11 $18.76 $6.43
Effect of exchange rate
Change in cash and equivalents -$59.45 -$38.51 -$16.54 -$41.95
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$113.72 -$250.16 -$65.58 -$89.13
Operating activities
Depreciation $15.11 $11.85 $9.22 $8.89
Business acquisitions & disposals
Stock-based compensation $34.1 $25.48 $20.22 $8.82
Total cash flows from operations -$117.35 -$228.82 $6.69 -$93.61
Investing activities
Capital expenditures -$7.97 -$9.82 -$9.57 -$0.59
Investments $18.56 $92.25 $73.65 -$158.3
Total cash flows from investing $10.58 $82.43 $64.09 -$158.89
Financing activities
Dividends paid
Sale and purchase of stock $21.19 $103.9 $2.13 $303.42
Net borrowings $50.52 $25.7 -$0.95
Total cash flows from financing $71.7 $129.6 $1.18 $303.42
Effect of exchange rate $0 -$0 -$0
Change in cash and equivalents -$35.07 -$16.79 $71.95 $50.92
Fundamentals
Market cap $125.10M
Enterprise value N/A
Shares outstanding 170.20M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity -8.99
Net debt/EBITDA N/A
Current ratio 1.12
Quick ratio N/A